Health Condition 1: K928- Other specified diseases of the digestive system Health Condition 2: N738- Other specified female pelvic inflammatory diseases
Conditions
Interventions
Intervention1: Group 3-Inj Rocuronium + inj Atracurium: The patients belonging to this group will be administered a combination of Rocuronium (0.3 mg/kg ) + atracurium (0.3 mg/kg) as half of the resp
Sponsors
DrVijeta Bajpai
Eligibility
Inclusion criteria
Inclusion criteria: 18 to 60 years of either sex belonging to the American Society of Anesthesiologists (ASA) Class I/II/III BMI of less than 35 kg/m2 Elective Laparoscopic surgeries Patients willing to participate in the study
Exclusion criteria
Exclusion criteria: Patient refusal. Significant cardiovascular disease Obstructive or restrictive pulmonary dysfunction hepato renal dysfunction Neuromuscular metabolic abnormality or endocrinology disorders History of substance abuse and psychiatric illness patients using antipsychotic medication or neuroleptics History of relevant drug allergy. Pregnant patients or breast feeding females Patient with difficult airway requiring succinylcholine Patient with history muscular dystrophies myasthenia gravis or any other diseases of neuromuscular junctions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Efficacy outcome To compare duration of deep neuromuscular blockade after initial intubating bolus Timepoint: Baseline Parameters At 15 min interval | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 To compare onset of action of intubating bolus dose of muscle relaxant. 2 To compare reversibility of muscle relaxant effect. 3 To compare quality of intubating condition. 4 To evaluate duration of action of maintenance doses of study drugs. Timepoint: baseline At 15 min;Safety outcome to compare complications and side effects (nausea, vomiting, respiratory depression) among the groups. Timepoint: | — |
Countries
India
Contacts
Public ContactDr Vijeta Bajpai
AIIMS Gorakhpur
Outcome results
None listed